# US 2025/0375421 A1 · Methods of using dmt

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375421 A1
- Document ID: US20250375421A1
- Status: Published application
- Kind: A1
- Application number: 19/310,559
- Filed: 2025-08-26
- Published: 2025-12-11
- Earliest claimed: 2023-03-09
- Inventors: William Shulman
- Web page: https://patentgrep.com/patent/US20250375421A1

## CPC

- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 9/0043: {Nose}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates in some aspects to methods for modulating and improving the subjective experience of N,N-dimethyltryptamine (DMT) by administering DMT after a long-acting tryptamine such as psilacetin, and in some embodiments, together with a benzodiazepine and/or ketamine, or in some further embodiments, together with a second long-acting psychedelic. In some aspects, disclosed methods are useful for treating medical conditions, such as mental health disorders and neurodegenerative disorders. In some aspects, disclosed methods are useful for improving health and wellbeing, such as in healthy people.

## Claims

### Claim 1

A method of improving an individual's subjective experience of DMT, comprising administering to the individual:
i. a long-acting tryptamine, or a pharmaceutically acceptable salt thereof; and
ii. DMT, or a pharmaceutically acceptable salt thereof;
wherein administering the long-acting tryptamine is prior to administering the DMT.

### Claim 2 (depends on 1)

The method of claim 1, wherein the long-acting tryptamine is psilacetin, psilocybin, or psilocin.

### Claim 3 (depends on 2)

The method of claim 2, wherein the long-acting tryptamine is psilacetin.

### Claim 4 (depends on 3)

The method of claim 3, wherein the psilacetin is administered at a dose of from about 5 to 50 mg, 10 to 40 mg, 15 to 30 mg, or 20 to 25 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the DMT is administered by inhalation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the DMT is administered between 1 and 5 times during the 5 hours following administering to the individual the long-acting psychedelic.

### Claim 7 (depends on 6)

The method of claim 6, wherein each dose of DMT is from about 5 to 50 mg, 10 to 30 mg, or 15 to 25 mg.

### Claim 8 (depends on 1)

The method of claim 1, further comprising administering to the individual a benzodiazepine, or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The method claim 8, wherein the benzodiazepine is any of alprazolam, bromazepam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, etizolam, flunitrazepam, flurazepam, flutoprazepam, halazepam, ketazolam, loprazolam, lorazepam, lormetazepam, midazolam, nimetazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, tetrazepam, and triazolam.

### Claim 10 (depends on 9)

The method of claim 9, wherein the benzodiazepine is lorazepam.

### Claim 11 (depends on 9)

The method of claim 9, wherein the lorazepam is administered at a dose of from about 0.5 to 2 mg.

### Claim 12 (depends on 8)

The method of claim 8, comprising administering the benzodiazepine prior to the long-acting tryptamine.

### Claim 13 (depends on 1)

The method of claim 1, further comprising administering to the individual ketamine, or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the ketamine is administered between 1 and 5 times during the 5 hours following administering to the individual the long-acting psychedelic.

### Claim 15 (depends on 14)

The method of claim 14, wherein each dose of ketamine is from about 5 to 50 mg, 10 to 30 mg, or 15 to 25 mg.

### Claim 16 (depends on 13)

The method of claim 13, wherein the ketamine is administered intranasally.

### Claim 17 (depends on 1)

The method of claim 1, further comprising administering to the individual a second long-acting psychedelic, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the second long-acting psychedelic is 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET) or 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT).

### Claim 19 (depends on 1)

The method of claim 1, wherein the individual's subjective experience of DMT is improved in at least one respect compared to the administration of an equal amount of DMT alone.

### Claim 20 (depends on 19)

The method of claim 19, wherein the improvement in at least one respect comprises a decrease in a physical or psychological side effect of DMT.

### Claim 21 (depends on 20)

The method of claim 20, wherein the physical or psychological side effect of DMT is any of disorientation, acute anxiety, emotional distress, diarrhea, nausea, vomiting, elevated heart rate, elevated blood pressure, dizziness, agitation, and muscle incoordination.

### Claim 22 (depends on 19)

The method of claim 19, wherein the improvement in at least one respect comprises an increase in a positive effect of DMT.

### Claim 23 (depends on 22)

The method of claim 22, wherein the positive effect of DMT is any of euphoria, positive mood, internal unity, external unity, transcendence of time and space, ineffability, paradoxicality, sacredness, and noetic quality.

### Claim 24 (depends on 19)

The method of claim 19, wherein the improvement in at least one respect comprises an increase in the score of any of the Mystical, Positive Mood, Transcendence of Time and Space, and Ineffability subscales of the 30-item revised Mystical Experience Questionnaire (MEQ30).

### Claim 25 (depends on 19)

The method of claim 19, wherein the improvement in at least one respect comprises a decrease in the score of any of the Fear, Grief, Physical Distress, Insanity, Isolation, Death, and Paranoia subscales of the Challenging Experience Questionnaire (CEQ).

### Claim 26

A method of improving an individual's subjective experience of DMT, comprising administering to the individual:
i. psilacetin, or a pharmaceutically acceptable salt thereof;
ii. DMT, or a pharmaceutically acceptable salt thereof;
iii. lorazepam, or a pharmaceutically acceptable salt thereof; and
iv. ketamine, or a pharmaceutically acceptable salt thereof;
wherein administering the psilacetin is prior to administering the DMT; and wherein the individual's subjective experience of DMT is improved in at least one respect compared to the administration of an equal amount of DMT alone.

### Claim 27 (depends on 1)

A kit, useful for the practice of the method of claim 1, comprising:
i. a long-acting tryptamine, or a pharmaceutically acceptable salt thereof;
ii. DMT, or a pharmaceutically acceptable salt thereof; and
iii. instructions for use.

### Claim 28 (depends on 27)

The kit of claim 27, comprising:
i. psilacetin, or a pharmaceutically acceptable salt thereof;
ii. DMT, or a pharmaceutically acceptable salt thereof;
iii. lorazepam, or a pharmaceutically acceptable salt thereof;
iv. ketamine, or a pharmaceutically acceptable salt thereof; and
v. instructions for use.
